Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update.

Fabricia Petronilho, Lucineia Gainski Danielski, Rafael Roesler, Gilberto Schwartsmann, Felipe Dal-Pizzol

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Gastrin-releasing peptide (GRP) is a neuropeptide that acts through G protein coupled receptors and is involved in signal transmission in both the central and peripheral nervous systems. Its receptor, gastrin-releasing peptide receptor (GRPR), is expressed by various cell types, and it is overexpressed in cancer cells. In recent years, studies have suggested the relationship of GRP and inflammatory diseases. RC-3095, a selective GRPR antagonist, was found to have antiinflammatory properties in models of arthritis, gastritis, uveitis and sepsis. Furthermore, GRP mediates air pollutioninduced airway hyperreactivity and airway inflammation in mice. In conclusion, GRP and its receptor are relevant to the inflammatory response, being a potential therapeutic target several diseases are related to inflammation.

Original languageEnglish (US)
Pages (from-to)172-177
Number of pages6
JournalInflammation & allergy drug targets
Volume12
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update.'. Together they form a unique fingerprint.

Cite this